(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 November 2009 (12.11.2009)

PCT

(10) International Publication Number
WO 2009/136352 A8

(51) International Patent Classification:
A61K 47/48 (2006.01) *C07K 14/71* (2006.01)

(21) International Application Number:
PCT/IB2009/051820

(22) International Filing Date:
4 May 2009 (04.05.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/050,574	5 May 2008 (05.05.2008)	US
61/050,569	5 May 2008 (05.05.2008)	US
61/050,544	5 May 2008 (05.05.2008)	US

(71) Applicant *(for all designated States except US)*: **CovX Technologies Ireland, Ltd.** [IE/IE]; Pottery Road Dun, Laoghaire County Dublin, Dublin (IE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DOPPALAPUDI, Venkata Ramana** [US/US]; CovX Technologies Ireland Limited 9381, Judicial Drive-Suite 200, San Diego, California 92121 (US). **LAI, Jing-Yu** [US/US]; CovX Technologies Ireland Limited 9381, Judicial Drive - Suite 200, San Diego, California 92121 (US). **LIU, Bin** [US/US]; CovX Technologies Ireland Limited 9381, Judicial Drive - Suite 200, San Diego, California 92121 (US). **LIU, Dingguo** [CN/US]; CovX Technologies Ireland Limited 9381, Judicial Drive - Suite 200, San Diego, California 92121 (US). **DESHARNAIS, Joel** [CA/US]; CovX Technologies Ireland Limited 9381, Judicial Drive - Suite 200, San Diego, California 92121 (US). **BHAT, Abhijit Suresh** [IN/US]; CovX Technologies Ireland Limited 9381, Judicial Drive - Suite 200, San Diego, California 92121 (US). **FU, Yanwen** [CN/US]; CovX Technologies Ireland Limited 9381, Judicial Drive - Suite 200, San Diego, California 92121 (US). **OATES, Bryan Douglas** [US/US]; CovX Technologies Ireland Limited 9381, Judicial Drive - Suite 200, San Diego, California 92121 (US). **CHEN, Gang** [US/US]; CovX Technologies Ireland Limited 9381, Judicial Drive - Suite 200, San Diego, California 92121 (US). **BRADSHAW, Curt William** [US/US]; CovX Technologies Ireland Limited 9381, Judicial Drive-Suite 200, San Diego, California 92121 (US).

(74) Agent: **BENSON, Gregg, C.**; Pfizer Inc., 150 East 42nd Street, New York, NY 10017 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:
25 November 2010

(15) Information about Correction:
see Notice of 25 November 2010

(54) Title: ANTI-ANGIOGENIC COMPOUNDS

(57) Abstract: The present invention provides VEGF binding peptides. In addition, the invention provides VEGF peptides conjugated to antibodies alone and in conjunction with other anti-angiogenic molecules. Various uses of the peptides and compounds are provided, including methods to treat disorders assoiated with abnormal angiogenesis.

WO 2009/136352 A8